Sugi Predict

Sugi Predict / Compounds / SCHEMBL19100705

SCHEMBL19100705

SCHEMBL19100705

CC(C)(C)OC(=O)NCc1c[nH]c2ccccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 2/20 0.58
▸ CTSS P25774 1/20 0.58
▸ CTSK P43235 1/20 0.58
▸ MAPT P10636 5/20 0.54
▸ MEN1 O00255 3/20 0.54
▸ KMT2A Q03164 3/20 0.54
▸ IDO1 P14902 1/20 0.54
▸ TACR1 P25103 3/20 0.54
▸ TP53 P04637 1/20 0.53
▸ LMNA P02545 2/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ PKM P14618 1/20 0.52
▸ TSHR P16473 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ BLM P54132 1/20 0.52
▸ KDM4E B2RXH2 1/20 0.51
▸ SSTR3 P32745 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ FAAH O00519 1/20 0.50
▸ ACE P12821 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5745010 0.87 MEN1 (0.67) MEN1KMT2ALMNACYP1A2PKM
SCHEMBL1850096 0.86 KMT2A (0.59) MAPTMEN1KMT2AIDO1LMNA
SCHEMBL24438127 0.85 MC1R (0.50) CTSLCTSSCTSKMAPTMEN1
SCHEMBL7846607 0.85 FAAH (0.58) CTSLCTSSCTSKMEN1KMT2A
SCHEMBL9797969 0.84 LMNA (0.53) CTSLCTSSCTSKMAPTMEN1
SCHEMBL7319151 0.82 IDO1 (0.58) CTSLCTSSCTSKMEN1KMT2A
SCHEMBL6300686 0.82 CTSL (0.59) CTSLCTSSCTSKMAPTMEN1
SCHEMBL22039141 0.82 MAPT (0.61) MAPTMEN1KMT2ALMNACYP1A2
SCHEMBL32678237 0.82 MEN1 (0.62) MAPTMEN1KMT2ALMNACYP1A2
SCHEMBL30561257 0.82 MAPT (0.61) MAPTMEN1KMT2ALMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3399968-B1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS PHARMATECH LTD (KY) 2021-10-20 — — EP disclosed
CN-109328059-B Selective inhibitors of clinically important mutants of EGFR tyrosine kinase CS制药技术有限公司 2021-08-17 — — CN disclosed
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase CS PHARMATECH LIMITED (KY) 2019-10-08 — — US disclosed
CN-109328059-A Selective inhibitors of clinically important mutants of EGFR tyrosine kinase CS制药技术有限公司 2019-02-12 — — CN disclosed
US-20190023689-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE HIGH GREAT INVESTMENT LIMITED (HK) 2019-01-24 — — US disclosed
EP-3399968-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS Pharmatech Limited (KY) 2018-11-14 — — EP disclosed
WO-2017120429-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS Pharmasciences, Inc. (US) 2017-07-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase EGFR, ERBB3, ERBB2 CTSL 2346/4885CTSS 1365/4885CTSK 1302/4885
US-20190023689-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE EGFR, ERBB3, ERBB2 CTSL 2346/4885CTSS 1365/4885CTSK 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.